Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares OutstandingShares Outstanding
Ratios

Medifast (MED) Accumulated Depreciation & Amortization (2016 - 2025)

Medifast's Accumulated Depreciation & Amortization history spans 16 years, with the latest figure at $14.2 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 12.08% year-over-year to $14.2 million; the TTM value through Dec 2025 reached $14.2 million, up 12.08%, while the annual FY2025 figure was $14.2 million, 12.08% up from the prior year.
  • Accumulated Depreciation & Amortization reached $14.2 million in Q4 2025 per MED's latest filing, up from $12.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $14.2 million in Q4 2025 to a low of $6.8 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $11.6 million, with a median of $12.7 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation & Amortization: soared 61.19% in 2022, then decreased 3.05% in 2024.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $6.8 million in 2021, then skyrocketed by 61.19% to $11.0 million in 2022, then increased by 19.37% to $13.1 million in 2023, then dropped by 3.05% to $12.7 million in 2024, then increased by 12.08% to $14.2 million in 2025.
  • Per Business Quant, the three most recent readings for MED's Accumulated Depreciation & Amortization are $14.2 million (Q4 2025), $12.7 million (Q4 2024), and $13.1 million (Q4 2023).